Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 28, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - May 28, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/28/17 - $20.5 million verdict for Childers, Schlueter & Smith, LLC
By a News Reporter-Staff News Editor at Drug Week Andy Childers and Neil Edwards, together with Paul Phillips, completed a jury trial against the pharmaceutical manufacturer Akorn, Inc., which resulted in a total award on behalf of their clients in the amount of $20.5 million. Akorn, Inc.' s Methylene Blue was used as a visualizing agent during A
4/28/17 - ABIVAXConfirms Trading Suspension
ABIVAX, an innovative biotechnology company targeting the immune system to eliminate viral diseases, confirms the suspension of trading on Euronext Paris effective as of April 28, 2017 at 11:29am CEST. ABIVAX also confirms that the results of ABX464-004, the 2 nd Phase IIa clinical trial of ABX464, its lead drug candidate in the treatment of HIV, w
4/28/17 - ABPI unveils its post-election wish-list [Syrian Arab News Agency]
Also critical, it says, is ensuring that the UK is in the top quartile of OECD countries for patient access to new medicines and vaccines by 2022. Again, the UK is not faring well against its peers on this: in the first year of launch, patients in France and Germany are around five times more likely to receive a new medicine than those in the UK. T
4/28/17 - Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102 [Palestine News Network]
-Adamas Pharmaceuticals, Inc. today announced the appointment of Richard A. King as Chief Operating Officer, reporting to Gregory T. Went, Ph.D., Chairman and Chief Executive Officer. Mr. King will be responsible for leading the Companys commercial organization and its established teams in marketing, market access, manufacturing, and distribution,
4/28/17 - Advanced Parenteral Drug Delivery Devices Market Global Professional Survey and In-depth Analysis Forecast to 2022
This report studies Advanced Parenteral Drug Delivery Devices in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.. This report focuses on top manufacturers in global market, with production,
4/28/17 - Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Clinical Study of Zoptrex?
Aeterna Zentaris Inc. will announce the top-line results of the ZoptEC Phase 3 clinical study of Zoptrex? in women with locally advanced, recurrent or metastatic endometrial cancer prior to the commencement of trading on Monday, May 1, 2017. The Company will host a conference call to discuss the results of the ZoptEC Phase 3 clinical study of Zop
4/28/17 - Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Womens Health [Sport360]
-Agile Therapeutics, Inc., a women`s healthcare company announced today that a presentation entitled An Update on Hormonal Contraception and The Changing U.S. Population will be presented by Co-Principal Investigator of the SECURE clinical trial, Anita Nelson, MD, Professor and Chair, Obstetrics and Gynecology, College of Osteopathic Medicine of th
4/28/17 - Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of positive data from its Phase 2 b clinical trial evaluating eptinezumab for the prevention of migraine. These data and additional study results are the topic of a podium presentation titled.
4/28/17 - Align Biopharma Announces New Identity Management Standard Available for Life Sciences Industry Input
By a News Reporter-Staff News Editor at Drug Week Align BiopharmaTM, a life sciences industry standards group that includes eight of the top 20 global pharmaceutical companies, announced its first technology standard is available for industrywide review and input. Therefore, the group is soliciting public review and input for its identity managem
4/28/17 - Allergan Teams Up With Media Mogul Wendy Williams to Debut the Patient Empowerment Campaign - Toilet Talk
By a News Reporter-Staff News Editor at Health& Medicine Week- Allergan plc, a global pharmaceutical company and leader in developing best-in-class treatment options for patients, has partnered with the American Gastroenterological Association, to announce the launch of Toilet TalkSM in celebration of IBS Awareness Month. At the center of this mu
4/28/17 - Allergy & Asthma Network to Advocate for Greater Access to Care, Research Funding at Annual Capitol Hill Day on May 4
Asthma and allergy patients, families, healthcare providers and patient advocates will join Allergy& Asthma Network in canvassing Capitol Hill on Thursday, May 4 to urge Congress to expand access to safe, effective and affordable healthcare, as well as continue funding for research. The meetings with members of Congress are part of the Network's 20
4/28/17 - Amneal Introduces Its First Nasal Spray: Generic Nasonex
By a News Reporter-Staff News Editor at Drug Week- HYPERLINK " https://amneal.com/"\ nAmneal Pharmaceuticals LLC has launched mometasone furoate nasal spray, the company's first pharmaceutical product in spray form. Manufactured in Branchburg, NJ, the product began shipping April 4th through wholesalers, distributors and directly to the trade.
4/28/17 - Amneal Pharmaceuticals, Bridgewater, N.J., Assigned Patent for Stabilization of Moisture-Sensitive Drugs
Amneal Pharmaceuticals, Bridgewater, New Jersey, has been assigned a patent developed by four co-inventors for "stabilization of moisture-sensitive drugs." The co-inventors are Marianthi Karakatsani, West Chester, Ohio, Anita Kumar, Brookhaven, New York, Devjibhai D. Kumbhani, Brookhaven, New York, and Pallapalayam M. Thangamathesvaran, Piscataway,
4/28/17 - Analyst Activity Aegis Reiterates Buy on Akebia Therapeutics (NASDAQ:AKBA)
Analyst Ratings For Akebia Therapeutics (NASDAQ:AKBA) Today, Aegis reiterated its Buy rating on Akebia Therapeutics (NASDAQ:AKBA) with a price target of $25.00. There are 1 hold rating, 6 buy ratings on the stock. The current consensus rating on Akebia Therapeutics (NASDAQ:AKBA) is Buy (Score: 2.86) with a consensus target price of $18.50 per share
4/28/17 - Analyst Activity Needham & Company LLC Raises Its Price Target On Akebia Therapeutics (NASDAQ:AKBA) to $18.00
Analyst Ratings For Akebia Therapeutics (NASDAQ:AKBA) Today, Needham & Company LLC raised its price target on Akebia Therapeutics (NASDAQ:AKBA) to $18.00 per share. There are 1 hold rating, 6 buy ratings on the stock. The current consensus rating on Akebia Therapeutics (NASDAQ:AKBA) is Buy (Score: 2.86) with a consensus target price of $17.83 per s
4/28/17 - ANDA approval times should be cut by two-thirds [Syrian Arab News Agency]
Girish Malhotra, President of EPCOT International, and CPhI Worldwide Annual Industry Report member, discusses the necessity of time reduction for Abbreviated New Drug Application approvals. This time can potentially be reduced to 15 days if the FDA modifies their review process. To avoid confusion, the FDA would have to create applications that cl
4/28/17 - AP Top News at 6:14 p.m. EDT
The test will be condemned by outsiders as yet another step in the North's push for a nuclear-tipped missile that can strike the U.S. mainland. A U.S. official, speaking on condition of anonymity to discuss sensitive matters, said the missile was likely a medium-range KN-17 ballistic missile. ATLANTA President Donald Trump reaffirmed his support
4/28/17 - Array Biopharma (ARRY) Appoints Shalini Sharp to Board [National News Agency (Lebanon)]
Ms. Sharp has been appointed to the Audit Committee of the Board. Ms. Sharp has served as Chief Financial Officer of Ultragenyx, a biopharmaceutical company focused on rare diseases, since 2012, where she is responsible for leading the corporate finance, strategy, and information technology functions and is a member of the company`s executive leade
4/28/17 - Array Biopharma Inc. Files SEC Form 4/A, Statement of Changes in Beneficial Ownership of Securities (Apr. 6, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on April 6, 2017. The SEC file number is 0001562180-17-001484.. A U.S. Securities and Exchange Commission filing is a formal doc
4/28/17 - Ascendis Pharma A/S Announces Upcoming Investor Presentations
Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will participate in two upcoming investor conferences in May. A live audio webcast of both events will be available in the Investors and News section of the
4/28/17 - Aspyrian announces the presentation of clinical data of its investigational therapy RM-1929 demonstrating significant anti-cancer response in recurrent Head and Neck Cancer patients who have failed all existing treatment options
Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy platform, today announced that findings from an ongoing clinical trial of its proprietary investigational compound, RM-1929, were presented at the American Head& Neck Society meeting, April 27, in San Die
4/28/17 - AstraZenecas lung cancer drug receives full approval in the EU [Sudan Tribune]
The European Commission has granted full marketing authorisation for AstraZenecas Tagrisso for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer. The full approval for Tagrisso is based on the results of the Phase III AURA3 trial.
4/28/17 - Avita Medical CEO Shareholder Letter and Quarterly Report
VALENCIA, Calif.& PERTH, Australia& LONDON Today, the CEO of Avita Medical Limited issued the following letter to shareholders:. As we await the completion of the clinical data analyses, the team has been assembling a host of other information required by the FDA. There is a reason why an FDA approval, more so for a Class 3 medical device such
4/28/17 - Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares
By a News Reporter-Staff News Editor at Drug Week Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, announced that it has commenced an underwritten public offering of $100 million of its common shares. J.P. Morgan Securities LLC and Morgan Stanley& Co. LLC are acting as joint book-runn
4/28/17 - Bharat Book Bureau: Brazil Generic Drug Market: Industry Trends
Generic drugs have been continuously gaining market share and currently account for a significant share of the total pharmaceutical market in Brazil. The report entitled "Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022" represents an in-depth analysis on the historical, current and future trends
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415